|
| Figure 4: Replication Kinetics of Y448H during Tegobuvir Treatment and Back-Calculation of Pre-Existing Y448H Levels in HCV-infected Genotype 1 Patients. Patients received either 40 or 120 mg BID of Tegobuvir (GS-9190) over 8 days. AS-PCR was performed on longitudinal samples collected during and after monotherapy. This allowed for the monitoring of Y448H replication kinetics during treatment to back-calculate pre-existing Y448H levels by linear regression analysis. |
